Merck & Co., Inc. (NYSE:MRK) Stock Holdings Reduced by Sicart Associates LLC

Sicart Associates LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 4.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 84,929 shares of the company’s stock after selling 3,675 shares during the period. Merck & Co., Inc. accounts for about 2.9% of Sicart Associates LLC’s holdings, making the stock its 10th biggest position. Sicart Associates LLC’s holdings in Merck & Co., Inc. were worth $7,170,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. JJJ Advisors Inc. acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $27,000. PRW Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $41,000. Aspire Private Capital LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $55,000. Thor Advisors LLC acquired a new stake in shares of Merck & Co., Inc. in the first quarter valued at approximately $69,000. Finally, Contravisory Investment Management Inc. boosted its holdings in shares of Merck & Co., Inc. by 19.7% in the second quarter. Contravisory Investment Management Inc. now owns 858 shares of the company’s stock valued at $72,000 after acquiring an additional 141 shares during the period. Institutional investors own 75.16% of the company’s stock.

In related news, EVP Frank Clyburn sold 25,000 shares of the stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $77.73, for a total transaction of $1,943,250.00. Following the completion of the sale, the executive vice president now directly owns 92,604 shares of the company’s stock, valued at $7,198,108.92. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Robert M. Davis sold 216,718 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $85.43, for a total value of $18,514,218.74. Following the sale, the chief financial officer now directly owns 354,378 shares of the company’s stock, valued at $30,274,512.54. The disclosure for this sale can be found here. 0.27% of the stock is owned by company insiders.

Shares of NYSE MRK traded down $1.07 during mid-day trading on Monday, hitting $83.40. 322,210 shares of the company were exchanged, compared to its average volume of 10,299,038. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.06 and a current ratio of 1.37. The business’s 50 day moving average is $83.19. Merck & Co., Inc. has a 1-year low of $64.97 and a 1-year high of $87.07. The company has a market capitalization of $215.91 billion, a price-to-earnings ratio of 19.22, a price-to-earnings-growth ratio of 1.71 and a beta of 0.56.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a return on equity of 42.84% and a net margin of 21.10%. The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. During the same period last year, the company earned $1.06 earnings per share. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, equities analysts anticipate that Merck & Co., Inc. will post 4.91 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.64%. The ex-dividend date of this dividend is Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio is presently 50.69%.

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price objective on Merck & Co., Inc. from $90.00 to $93.00 and gave the company an “overweight” rating in a report on Friday, June 14th. Goldman Sachs Group assumed coverage on Merck & Co., Inc. in a report on Tuesday, May 28th. They issued a “neutral” rating and a $85.00 price objective for the company. UBS Group increased their price objective on Merck & Co., Inc. from $87.00 to $88.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Morgan Stanley increased their price objective on Merck & Co., Inc. from $84.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, June 21st. Finally, Citigroup increased their price objective on Merck & Co., Inc. from $84.00 to $95.00 and gave the company a “buy” rating in a report on Friday, June 21st. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $90.36.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: How do investors use RSI to grade stocks?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.